Karma Ventures

Karma Ventures operates from Tallinn with a tightly defined thesis: invest in highly technical European software companies with exceptional commercial traction at Series A. The firm does not chase pre-seed deals or build out an early-stage portfolio. It writes a small number of considered checks per year into companies that have already demonstrated meaningful product-market fit. Health IT and healthcare software companies that match this profile are within scope.

The thesis assumes that the moments of greatest uncertainty in a venture-backed company’s life cycle are not at inception but at the transition from product-market fit to scale, when capital intensity rises and execution must accelerate. Karma is built to underwrite that moment specifically, which is why the firm avoids earlier stages where the technical and commercial questions are still open. Healthcare investments under this thesis tend to share certain traits: a clear technical wedge, identifiable enterprise or institutional customers, demonstrated commercial momentum, and a credible path to multi-region scale. The portfolio leans toward enterprise software and infrastructure rather than consumer or service businesses.

Karma writes Series A checks generally between $1M and $5M, with the willingness to lead and to follow on into Series B and beyond. Geographically, the firm is anchored in the Baltic states and operates across Europe, with particular density in companies with strong Baltic or Nordic founder roots. The Series A focus means Karma expects companies to have working products, paying customers, and clear unit economics by the time a check is written. Diligence is correspondingly more rigorous on commercial metrics than at earlier-stage firms.

The partnership is small and technically literate. Partners come from operating backgrounds in addition to investing, which shows up in diligence conversations that engage with product architecture and engineering organization rather than only with revenue and growth. Founders should expect substantive technical questions and a willingness to spend time on the engineering side of the business.

Post-investment, Karma’s most distinctive value is on technical hiring, engineering organization design, and structuring follow-on rounds with later-stage European and global investors. The firm has working relationships with growth funds in London, Berlin, and the US that can lead Series B and Series C financings. Board engagement is focused and substantive rather than ceremonial. For healthcare software founders at Series A with strong technical teams and clear commercial traction, Karma is a logical lead investor candidate. The fit is weaker for companies that need deep clinical or regulatory specialism, which sits outside the firm’s competency, and for those at pre-seed or seed stage, which is outside the mandate. Founders considering Karma should plan for a process focused on substance and should bring detailed engineering and commercial materials to early conversations. The firm is direct in its feedback and tends to make decisions quickly when conviction develops.